Company intelligence / Profile preview

iHeart Japan

Kyoto, Kyoto, Japan

Ownership: Private
Development stage: Other

Overview

iHeart Japan is a clinical-stage biotechnology company focused on developing regenerative medicine therapies for cardiovascular diseases. Spun out from Kyoto University, the company utilizes induced pluripotent stem cell (iPSC) technology to create functional cardiomyocyte sheets. These sheets are designed to be transplanted onto the surface of a failing heart to restore cardiac function and promote tissue repair. The company's lead program, IHJ-01, is currently in clinical development for the treatment of severe heart failure, representing a potential paradigm shift in the management of end-stage cardiac conditions.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyInduced pluripotent stem cell derived therapy
Industry: Biotech

Drug pipeline

1 asset

IHJ-301

Preclinical

Partnerships

Kyoto University

Beyond the preview

Go deeper on iHeart Japan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iHeart Japan.

Explore the full profile